Metastatic

HER2 +

3rd Line or Later

BRS0131
Phase I/II IV
Zotatin (eFT226)
in Selected
Advanced Solid
Tumor
Malignancies

PI: Caswell-Jin
Sponsor:
eFFECTOR
Therapeutics, Inc.

Priority 1

BRS0142
Phase I/II Open Label
Dose Escalation and
Dose Expansion Study
to Evaluate Safety,
Tolerability, Dosimetry,
and Preliminary
Efficacy of HER2
Directed Radioligand
CAM-H2 in
Advanced/Metastatic
HER2-Positive Breast,
Gastric, &
Gastro-Esophageal
Junction Cancer

PI: Aparici
Sponsor: Precirix NV

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Trial Posting
Link
Extension Study
Immunotherapy

Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu